ijms-logo

Journal Browser

Journal Browser

Molecular Research on Depression—2nd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Neurobiology".

Deadline for manuscript submissions: 20 December 2025 | Viewed by 1526

Special Issue Editor


E-Mail Website
Guest Editor
Department of Human Physiology, Institute of Medical Sciences, Medical College of Rzeszów University, Kopisto 2a, 35-310 Rzeszow, Poland
Interests: antidepressants; glutamte receptors; Epigenetic; depression
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Depressive disorders are responsible for a significant burden of disease in the human population. This problem affects not only individuals but also family members and society as a whole. Therefore, it is a serious social and economic problem in the 21st century. For several decades, many theories of depression have been formulated, on which modern pharmacotherapy is based. The importance of noradrenergic, serotonergic, dopaminergic, or glutamate transmission disturbances in the pathogenesis of depression seems to be undeniable. This is confirmed by drugs that modulate the turnover of these neurotransmitters in the brain and in many cases reduce (or eliminate) symptoms of depression. Unfortunately, 30% (or even more) of depressive patients do not respond to traditional treatment and first-line treatment options. The key to developing new, more effective therapeutic strategies is to understand the molecular mechanisms underlying depressive disorders. In recent years, a large body of work has elucidated some of the molecular/cellular alterations that are critically involved in depression. Improving serotonergic transport to eventually compensate for serotonin deficiencies in the synaptic gap is known to have a health-promoting effect in patients diagnosed with depression. Similarly, the regulation of glutamate levels, or dopamine metabolism, has positive effects on aspects related to mood or motivation. Further research is ongoing and brings us closer to better understanding the basics of neurotransmission systems and the regulation of brain circuits in depression. Therefore, we invite and encourage everyone to submit the results and conclusions of new discoveries that may lead to novel therapeutic interventions in the future.

Dr. Magdalena Sowa-Kućma
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • depression
  • epigenetics
  • animal models of depression
  • serotonin
  • glutamate
  • dopamine
  • neurotrophic factors

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

39 pages, 1177 KB  
Review
Gepirone for Major Depressive Disorder: From Pharmacokinetics to Clinical Evidence: A Narrative Review
by Natalia Gałka, Emilia Tomaka, Julia Tomaszewska, Patrycja Pańczyszyn-Trzewik and Magdalena Sowa-Kućma
Int. J. Mol. Sci. 2025, 26(19), 9805; https://doi.org/10.3390/ijms26199805 - 8 Oct 2025
Viewed by 1170
Abstract
Gepirone, a selective 5-hydroxytryptamine (serotonin) 1A (5-HT1A) receptor agonist, offers a promising strategy for treating mood and anxiety disorders. The therapeutic importance of 5-HT1A modulation is well established, as these receptors regulate serotonergic neurotransmission both presynaptically, in the somatodendritic regions [...] Read more.
Gepirone, a selective 5-hydroxytryptamine (serotonin) 1A (5-HT1A) receptor agonist, offers a promising strategy for treating mood and anxiety disorders. The therapeutic importance of 5-HT1A modulation is well established, as these receptors regulate serotonergic neurotransmission both presynaptically, in the somatodendritic regions of raphe neurons, and postsynaptically, in structures including the hippocampus, neocortex, septum, amygdala, and hypothalamus. Gepirone exhibits a distinctive pharmacological profile, acting as a full agonist at presynaptic autoreceptors and a partial agonist at postsynaptic receptors, with high affinity for 5-HT1A and much lower affinity for 5-HT2A receptors. Its effects on serotonergic signaling are time-dependent. Acute administration suppresses serotonergic firing through autoreceptor activation, while chronic treatment induces autoreceptor desensitization, leading to enhanced 5-HT release in projection areas. This process is complemented by partial agonism at postsynaptic 5-HT1A receptors, which further supports long-term neuromodulation. This article provides an integrated overview of gepirone’s mechanism of action, bridging receptor pharmacology, neurophysiological adaptations, and therapeutic implications. Particular emphasis is placed on the compound’s unique dual role in regulating serotonergic tone over time, a feature that differentiates it from other 5-HT1A-targeting agents. By linking molecular mechanisms to clinical outcomes, we highlight gepirone’s potential advantages in efficacy, safety, and tolerability compared with conventional antidepressants. This comprehensive perspective underscores gepirone as a paradigmatic example of selective 5-HT1A modulation and offers novel insights into the development of targeted treatments for depression and anxiety. Full article
(This article belongs to the Special Issue Molecular Research on Depression—2nd Edition)
Show Figures

Figure 1

Back to TopTop